Literature DB >> 35221551

IACTS position statement on "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization": section 7.1-a consensus document.

Om Prakash Yadava1, Pradeep Narayan2, Chandrasekar Padmanabhan3, Lokeswara Rao Sajja4, Kunal Sarkar5, Praveen Kerala Varma6, Vivek Jawali7.   

Abstract

American College of Cardiology (ACC), American Heart Association (AHA) and Society for Cardiovascular Angiography and Interventions (SCAI) recently released the Clinical Practice Guidelines for myocardial revascularization [1]. The guidelines were the felt need of the fraternity and this single all-encompassing document, relegating the previous six guidelines on the subject to archives, is indeed welcome. However, the downgrading of coronary artery bypass surgery for stable multivessel coronary artery disease and its bracketing with percutaneous coronary interventions has caused a lot of anguish in the surgical fraternity. This document presents the official viewpoint of the Indian Association of Cardiovascular and Thoracic Surgeons on the matter. © Indian Association of Cardiovascular-Thoracic Surgeons 2022.

Entities:  

Keywords:  2021 ACC/AHA guideline on coronary artery revascularisation; CABG; Clinical practice guidelines; Myocardial revascularisation; STS/AATS/LACES/EACTS/ESC/IACTS; Stable ischemic heart disease

Year:  2022        PMID： 35221551      PMCID： PMC8857365          DOI： 10.1007/s12055-022-01329-y

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN： 0970-9134


  41 in total

1.  A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty.

Authors:  E L Hannan; M J Racz; B D McCallister; T J Ryan; D T Arani; O W Isom; R H Jones
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

Review 2.  2018 ESC/EACTS Guidelines on myocardial revascularization.

Authors:  Miguel Sousa-Uva; Franz-Josef Neumann; Anders Ahlsson; Fernando Alfonso; Adrian P Banning; Umberto Benedetto; Robert A Byrne; Jean-Philippe Collet; Volkmar Falk; Stuart J Head; Peter Jüni; Adnan Kastrati; Akos Koller; Steen D Kristensen; Josef Niebauer; Dimitrios J Richter; Petar M Seferovic; Dirk Sibbing; Giulio G Stefanini; Stephan Windecker; Rashmi Yadav; Michael O Zembala
Journal:  Eur J Cardiothorac Surg       Date:  2019-01-01       Impact factor: 4.191

3.  2018 ESC/EACTS Guidelines on myocardial revascularization.

Authors:  Franz-Josef Neumann; Miguel Sousa-Uva; Anders Ahlsson; Fernando Alfonso; Adrian P Banning; Umberto Benedetto; Robert A Byrne; Jean-Philippe Collet; Volkmar Falk; Stuart J Head; Peter Jüni; Adnan Kastrati; Akos Koller; Steen D Kristensen; Josef Niebauer; Dimitrios J Richter; Petar M Seferovic; Dirk Sibbing; Giulio G Stefanini; Stephan Windecker; Rashmi Yadav; Michael O Zembala
Journal:  Eur Heart J       Date:  2019-01-07       Impact factor: 29.983

4.  Revascularization versus medical therapy for the treatment of stable coronary artery disease: A meta-analysis of contemporary randomized controlled trials.

Authors:  Jari A Laukkanen; Setor K Kunutsor
Journal:  Int J Cardiol       Date:  2020-10-15       Impact factor: 4.164

5.  Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.

Authors:  Daniel J F M Thuijs; A Pieter Kappetein; Patrick W Serruys; Friedrich-Wilhelm Mohr; Marie-Claude Morice; Michael J Mack; David R Holmes; Nick Curzen; Piroze Davierwala; Thilo Noack; Milan Milojevic; Keith D Dawkins; Bruno R da Costa; Peter Jüni; Stuart J Head
Journal:  Lancet       Date:  2019-09-02       Impact factor: 79.321

6.  Selection of surgical or percutaneous coronary intervention provides differential longevity benefit.

Authors:  Peter K Smith; Robert M Califf; Robert H Tuttle; Linda K Shaw; Kerry L Lee; Elizabeth R Delong; R Eric Lilly; Michael H Sketch; Eric D Peterson; Robert H Jones
Journal:  Ann Thorac Surg       Date:  2006-10       Impact factor: 4.330

Review 7.  PCI and CABG for Treating Stable Coronary Artery Disease: JACC Review Topic of the Week.

Authors:  Torsten Doenst; Axel Haverich; Patrick Serruys; Robert O Bonow; Pieter Kappetein; Volkmar Falk; Eric Velazquez; Anno Diegeler; Holger Sigusch
Journal:  J Am Coll Cardiol       Date:  2019-03-05       Impact factor: 24.094

Review 8.  The Long-Awaited Revascularization Guidelines Are Out: What's In Them?

Authors:  Kendra J Grubb; Ajay J Kirtane
Journal:  Circulation       Date:  2021-12-09       Impact factor: 29.690

9.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

10.  Initial Invasive or Conservative Strategy for Stable Coronary Disease.

Authors:  David J Maron; Judith S Hochman; Harmony R Reynolds; Sripal Bangalore; Sean M O'Brien; William E Boden; Bernard R Chaitman; Roxy Senior; Jose López-Sendón; Karen P Alexander; Renato D Lopes; Leslee J Shaw; Jeffrey S Berger; Jonathan D Newman; Mandeep S Sidhu; Shaun G Goodman; Witold Ruzyllo; Gilbert Gosselin; Aldo P Maggioni; Harvey D White; Balram Bhargava; James K Min; G B John Mancini; Daniel S Berman; Michael H Picard; Raymond Y Kwong; Ziad A Ali; Daniel B Mark; John A Spertus; Mangalath N Krishnan; Ahmed Elghamaz; Nagaraja Moorthy; Whady A Hueb; Marcin Demkow; Kreton Mavromatis; Olga Bockeria; Jesus Peteiro; Todd D Miller; Hanna Szwed; Rolf Doerr; Matyas Keltai; Joseph B Selvanayagam; P Gabriel Steg; Claes Held; Shun Kohsaka; Stavroula Mavromichalis; Ruth Kirby; Neal O Jeffries; Frank E Harrell; Frank W Rockhold; Samuel Broderick; T Bruce Ferguson; David O Williams; Robert A Harrington; Gregg W Stone; Yves Rosenberg
Journal:  N Engl J Med       Date:  2020-03-30       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.